In the realm of drug development, the transition from preclinical research to clinical trials is a critical juncture often fraught with uncertainty. One of the key challenges lies in accurately predicting how a new drug will behave in humans based on preclinical findings, particularly concerning its cardiac safety. This is where CiPA (Comprehensive in vitro Proarrhythmia Assay)...